H epatocellular carcinoma (HCC) is a primary liver tumor that causes high mortality and remains a global challenge with the current limited treatments available. (1) HCC is the sixth most commonly diagnosed cancer and accounts for nearly 700,000 deaths worldwide per annum. (2) Current curative therapies such as resection, transplantation, local ablation and transarterial percutaneous chemoembolization have limited efficacy. (3) Therefore, it is imperative to develop novel therapeutic strategies against HCC. miRNAs are endogenous, non-coding RNAs (19) (20) (21) (22) (23) (24) (25) 
nucleotides) that negatively regulates
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Physical approaches like electroporation have limited use for the functional delivery of miRNAs, while viral vectors despite having high transfection efficiency may be toxic and oncogenic. (13, 14) Non-viral carriers derived from metals, dendrimers, lipids and polymers have also been tested for miRNA based HCC therapy, but these systems are also associated with low in vivo stability, high drug-leaching properties, toxicity, and the possibility of undesirable immune responses. (2, 15, 16) Recently, peptide based NPs have gained significant interest, owing to unique features that includes their inherent biocompatibility, biodegradability, ease of synthesis, reduced cost and tunable structures for functionalization. However, peptide based systems may have an inherent drawback of being susceptible to enzymatic degradation. Inclusion of unnatural amino acid residues like, a,b-dehydrophenylalanine (DF) in peptide sequences has been reported to greatly enhance enzymatic stability. (17, 18) For selective targeting of NPs to tumor cells, it is highly desirable to derivatize them with specific ligands that can actively interact with the cognate receptors overexpressed on the tumor cell surface. Asialoglycoprotein receptor (ASGPR) is known to be primarily expressed on hepatocytes and minimally expressed on extra hepatic cells. Various ligands have been described for the ASGPR receptor including lactobionic acid, galactose and asialofeutin, offering an opportunity for developing specific delivery of therapeutics for ASGPR. (19) In this study, we have evaluated the self-assembly of a set of short cationic peptides containing DF residue Arg-DPhe (RDF), His-DPhe (HDF), Arg-DPhe-Arg (RDFR) and His-DPhe-His (HDFH) and found that a dipeptide RDF self-assembled into uniform spherical nanostructures with an average size of 20 nm. To achieve liver tumor targeting, we conjugated RDF NPs with LA. RDF-LA NPs efficiently condensed miR199a-3p and displayed a significantly enhanced cellular uptake, biocompatibility, target specificity and efficacy in in vitro experiments. Administration of RDF-LA/ miR NPs in HCC tumor bearing nude mice achieved a significant accumulation at the tumor site and enhanced antitumor activity. Taken together, our findings suggest that RDF-LA/miR NPs could potentially serve as a safe and promising platform for targeted miRNA based therapy.
Materials and Methods

SYNTHESIS OF PEPTIDES
Details of synthesis of peptides, (20, 21) characterization of NPs, miR-199a-3p condensation with RDF-LA NPs, stability of RDF-LA/miR NPs in the presence of serum and RNase A, cellular uptake of NPs in HCC cells, evaluation of miR-199a-3p delivery by qRT-PCR, in vitro cell proliferation assay, wound healing assay and cellular apoptosis are provided in the supporting information.
SELF-ASSEMBLY OF PEPTIDES
Self-assembly of peptides (RDF, RDFR, HDF and HDFH) was initiated by mixing 20 ll of peptide solutions (peptides dissolved in solvents like ethanol/ 1,1,1,3,3,3-hexa-fluoro-2-propanol (HFIP) /Isopropanol (IPA)(Merck, Germany)) with 1ml of nuclease free water (Gibco, USA) to a final peptide concentration of 1-5mg/ml. The solutions were kept undisturbed at room temperature for 1hr before being used in any experiment.
DERIVATIZATION OF RDF NPs WITH LA
N-terminal of RDF NPs was derivatized with LA (Sigma-Aldrich, USA) using EDC/NHS (1-ethyl-3(-3-dimethylaminopropyl) carbodiimide/ N-hydroxysuccinimide chemistry as described earlier. (22) In brief, EDC (2 mM) and NHS (5 mM) were added to LA solution (3.2mM) in 2-ethane sulphonic acid (MES) buffer (0.1M, pH 6.0) and incubated for 30 min at room temperature to form stable intermediates. 2-Mercaptoethanol (1.4 ll, final concentration of 20 mM) was added to quench excess EDC. The reaction mixture was added to RDF NPs solution at 1:1 molar ratio and allowed to react for 24 hr at room temperature. After 24 hr, LA-conjugated NPs were separated from unreacted LA by centrifugation at 6,000 rpm using 3 kDa cut-off filter tubes (Millipore, Billerica, MA) and washed 3 times with nuclease free water.
PREPARATION OF RDF-LA/ miR NPs
RDF-LA NPs were mixed with fixed amount of miR-199a-3p (MISSION microRNA mimic hsamiR-199a-3p, Sigma, USA) at different ratios of RDF-LA NPs: miR-199a-3p (w/w), vortex for 30sec to initiate the complex formation and then incubated at room temperature for 30 min.
ANIMAL EXPERIMENT
The animal studies were carried out in accordance with the internal Institutional Animal Care and Use committee guidelines at the Institute of Liver & Biliary Sciences (approval no: IAEC/ILBS/14/03). All animals were treated with humane care. They were kept in individual ventilated cages and fed with autoclaved water and irradiated food ad libitum. Male BALB/c nude mice of weight 20-22g (age 4-6 weeks) were kind gift from Piramal Healthcare (Mumbai, India).
In Vivo Biodistribution Study
HCC tumors were generated by subcutaneous injection of 5 3 10 6 Huh7 cells suspended in 200 ul of PBS into the scapular region of 7-8 week old BALB/c nude mice. Once tumor masses became 500mm 3 , mice were randomized in treatment groups of naked miR-199a-3p, RDF/miR NPs and RDFLA/miR NPs. Mice were injected intravenously with a single dose (50 mg) of cyanine5(Cy5)-labeled miR-199a-3p loaded in different formulations. After that, mice were anesthetized with ketamine/xylazine (0.1ml/20g mice, intraperitonial). Anesthetized mice were imaged in small animal in vivo imaging system (Kodak FX Pro, USA) in Xray and florescence mode at 1hr, 4hr and 24 hr time points. After 24hr, mice were euthanized and organs were excised and imaged ex vivo. Thereafter, tissues were collected and fixed in 4% paraformaldehyde (Sigma,USA) for 12h followed by 12h incubation in a 30% sucrose/PBS solution at 4 8C. Fixed tissue samples were then placed into block holders containing tissue tek-O.C.T. (optimal cutting temperature) and snapfrozen on dry ice. The tissue blocks were sectioned (5 lm) using cryostat and nuclei were stained with DAPI (4,6-diamidino-2-phenylindole) for 15 min at room temperature. Red fluorescence of Cy5-miR199a-3p and blue fluorescence of DAPI were detected by confocal microscope (Leica TCS SP8, Germany).
In Vivo Tumor Regression Study
When palpable tumors (200mm 3 ) were established, mice were randomly divided into five different groups, PBS, naked miR-199a-3p, RDF-LA/NC (dose of negative control miRNA, 1mg/kg), RDF-LA/miR199a-3p NPs(dose of miR-199a-3p, 1mg/kg), RDF/ miR NPs (dose of miR-199a-3p, 1mg/kg), (n56). Dose of NPs formulations was given after every 3 days for 28 days by intravenous injection. Tumor dimensions and body weight were recorded two times per week. Tumor volumes were estimated as follows: V (mm 3 ) 5 (length 3 width 2 )/2. Finally, the mice were sacrificed 2 days after the final injection, major organs (heart, liver, spleen, lung and kidney) and tumor were excised and their weights were recorded. Blood samples were collected for analysis of alanine aminotransferase (ALT) aspartate aminotransferase (AST) and creatinine levels. For immunotoxicity studies, mice (n56) were intravenously injected with RDF-LA/miR NPs, RDF/miR NPs and PBS. After 48 hr, blood samples were collected and tumor necrosis factoralpha (TNF-a), Interlukin-6 (IL-6), Interlukin-1 beta (IL-1b) and GM-CSF (granulocyte macrophagecolony stimulating factor) cytokine levels in serum of mice were analysed by cytokine multiplex assay as per manufacturer's protocol (Thermofisher, USA).
STATISTICAL ANALYSIS
Data were analyzed using the GraphPad Prism Software (version 5; GraphPad Software Inc.) and are represented as the mean 6 SD. All experiments were performed in triplicates unless otherwise indicated. Statistical significance was performed by using student t-test for two groups and analysis of variance (ANOVA) for more than two groups followed by Tukey's post-hoc method as appropriate. Survival curve was plotted using the Kaplan-Meier method and compared by the log-rank test. P < 0.05 was considered statistically significant.
Further details of the materials and methods are provided in Supporting Information.
Results
SYNTHESIS OF PEPTIDES AND THEIR SELF-ASSEMBLY
All peptides were synthesized and purified as described in the supporting information. (Supporting Table S1 ). Peptide self-assembly was determined at different concentrations (1-5mg/ml). All peptides selfassembled to form nanostructures at 1mg/ml concentration. As determined by dynamic light scaterring (DLS), the arginine based peptides (RDF and RDFR) formed nanostructures of a hydrodynamic diameter and zeta potential of 150nm (0.06 6 0.01, PDI) (131 6 1.7mV) and 432nm (0.7 6 0.03, PDI) (140 6 1.2mV) respectively. Histidine based peptides, HDF and HDFH, formed particles of size 442nm (0.1 6 0.01, PDI) (10.67 6 0.1mV) and 200nm (0.5 6 0.1, PDI) (113.4 6 0.45mV) respectively (Table  1) . Transmission electron microscopy (TEM) showed the formation of uniform vesicular structures with average size of 20nm and 50nm for RDF and RDFR respectively. On the other hand, HDF and HDFH formed pleomorphic structures with particle size of 32nm and 22nm respectively (Supporting Fig. S1 ). Since RDF NPs formed stable positively charged and monodispersed nano-sized particles, further studies were carried out only with RDF NPs.
PREPARATION AND CHARACTERIZATION OF RDF-LA/miR NPs
RDF NPs were derivatized with LA to form RDF-LA NPs (Fig. 1A) , purified by HPLC and the conjugation was confirmed using mass spectrometry (Supporting Fig. S2 ). In DLS experiments, an increase in hydrodynamic diameter from 150 6 8.9nm to 310 6 30nm was observed for RDF-LA NPs (Supporting Table S2 ). TEM images also showed an increase in particle size from 20nm to 40nm. Notably the NPs retained their homogenous vesicular shape after derivatization with LA (Supporting Fig. S3 ). A decrease in zeta potential was observed from 131 6 3 (RDF) to 1 13.24 6 0.14 (RDF-LA), which also indicated the formation of derivatized NPs, RDF-LA NPs (Supporting Table S2 ).
CONDENSATION OF miRNA WITH RDF-LA NPs
Condensation of miR-199a-3p with RDF-LA NPs was determined by gel retardation assay at different ratios (20:1, 50:1, 100:1 and 200:1) of RDF-LA NPs: miR199a-3p (w/w). Complete retardation of miR-199a-3p was observed at 50:1, whereas naked miR-199a-3p migrated to bottom of the gel suggesting the complex formation of RDF-LA NPs with miR-199a-3p (Fig. 1B ).
After complexation with miR-199a-3p, the average zeta potential of RDF-LA NPs decreased to 2.54 6 0.01 mV from 13.24 6 0.14mV. RDF-LA/ miR NPs showed a hydrodynamic diameter of 350 6 37nm (0.3 6 0.02, PDI) (Fig. 1C) . Vesicular nanostructure with particle size of 60nm was observed by TEM (Fig. 1D ). The loading of miRNA and its release from RDF-LA NPs was determined under different solution conditions. miRNA loading capacity of RDF-LA NPs was found to be 2.9 6 0.2% whereas in vitro studies showed miRNA release of 82% at pH 5, while 45-50% release at pH 7.4 and plasma in 120hr (Supporting Fig. S4 ).
STABILITY OF RDF-LA/miR NPs IN SERUM AND TO RNase A
Agarose gel electrophoresis showed a clear band of RDF-LA/miR NPs (50:1 w/w) upto 6 hr after RNase A treatment while naked miR-199a-3p was found to be fully degraded (Fig. 1E) . DLS experiment showed no significant change in hydrodynamic diameter of RDF-LA/miR NPs in serum upto 12 hr (Fig. 1F) .
CELLULAR UPTAKE AND INTRACELLULAR TRAFFICKING OF RDF-LA/miR NPs IN VITRO
The transfection efficiency of Cy3-miR-199a-3p loaded NPs was examined by flow cytometry. It was found that RDF-LA/miR NPs exhibited significantly higher cellular uptake than RDF/miR NPs (73% vs 47% in Huh7 cells). To investigate whether the entry of RDF-LA/miR NPs was mediated through ASGPR receptor, lactose pretreated HCC cells were treated with RDF-LA/miR NPs or RDF/miR NPs. A reduced cellular uptake in Huh7 cells was observed in case of RDF-LA/miR NPs from (73% to 49%). The uptake of RDF/miR NPs remains unaffected in Huh7 cells (45%) (Fig. 2A,B) . Similar results were observed on HepG2 cells (another ASGPR positive HCC cell line) (Supporting Fig. S5 ). Intracellular trafficking of NPs was investigated using confocal microscopy. RDF-LA/ miR NPs showed higher fluorescence signals in cytoplasm as compared to RDF/miR NPs. Lysotracker green was used to determine lysosomal co-localization of RDF-LA/miR NPs. The internalized RDF-LA/ miR NPs predominantly showed a punctate distribution pattern with minimal lysosomal localization in Huh7 cells. Similar pattern was observed in case of RDF-LA/miR NPs (Fig. 2C) . 
DELIVERY OF miR-199a-3p AND SUPPRESSION OF TARGET GENE (mTOR) EXPRESSION
To investigate the successful delivery of miR-199a-3p, relative expression of miR-199a-3p was determined using real time PCR in Huh7 cells that were transfected with different formulations. Significantly enhanced expression level (over 500 fold) of miR199a-3p was recorded in cells transfected with RDF-LA/miR NPs as compared to RDF-LA/NC NPs. miR-199a-3p delivery efficiency of RDF-LA NPs was comparable to that achieved with siPORT (Commercially available transfection reagent, positive control). Cells transfected with RDF-LA/miR NPs showed 2.3 fold enhanced expression of miR-199a-3p compared to RDF/miR NPs (Fig. 3A) .
We evaluated the levels of mTOR expression both at mRNA and protein level after miR-199a-3p transfection in Huh7 cells using different formulations. Compared to untreated cells, RDF-LA/miR NPs and RDF/miR NPs treated cells showed downregulation of mTOR mRNA by 57% and 38% respectively (Fig. 3B) . Western blotting analysis showed 62% and 39% knockdown in mTOR protein expression by RDF-LA/miR NPs and RDF/miR NPs respectively. Downregulation of mTOR protein expression using RDF-LA/miR NPs was comparable to that achieved with siPORT (Fig. 3C,D) .
FUNCTIONAL EFFICACY OF RDF-LA/miR NPs IN HCC CELLS
miR-199a-3p is known to influence the control of proliferation, migration and apoptosis. (23, 24) In order The effect of different formulations on cell migration was investigated using the wound healing assay. RDF-LA/miR NPs treated Huh7 cells exhibited closure of wound by 20%, while 58% in RDF/miR NPs treated and 88% in untreated cells after 24 hr (Fig. 4B,C) .
The level of apoptosis in Huh7 cells was evaluated by the AnnexinV-FITC apoptosis assay using flow cytometry. RDF-LA/miR NPs were shown to induce 32% apoptosis in Huh7 cells while24% cell apoptosis was observed in case of RDF/miR NPs. Minimal apoptosis was found in untreated (0.7%) and RDF-LA/NC NPs cells (5.6%; Fig. 4D,E) . These results illustrated that RDF-LA/miR NPs facilitated functional delivery of miR-199a-3p into HCC cells and thereby led to an enhanced anti-tumor activity in vitro.
TISSUE DISTRIBUTION OF RDF-LA/miR NPs IN HCC XENOGRAFT MOUSE MODEL
We examined the biodistribution of Cy5-RDF-LA/ miR NPs, Cy5-RDF/miR NPs and Cy5-naked miR199a-3p in tumor bearing mice after their intravenous administration.
Cy5-RDF-LA/miR NPs were detected in the tumor at 1hr with the highest intensity at 4hr. The fluorescence signals were reduced after 24hr post injection (Fig. 5A ). After 24hr, organs were excised and imaged (Fig. 5B) . In the tumor, Cy5-RDF-LA/miR NPs exhibited 8.6 fold higher florescence signals as compared to Cy5-naked miR199a-3p and 4 fold higher fluorescence signals compared to Cy5-RDF/miR NPs. RDF/miR NPs displayed higher accumulation in lungs as compared to liver and kidney, possibly due to the interaction with serum proteins reflecting their passive targeting. (25) Out of the three formulations, naked miR-199a-3p exhibited the highest fluorescence signal in the kidneys, which may suggest its clearance from the body. No detectable signals were observed in spleen and heart for any of the formulations (Fig. 5C ). Confocal microscopy also showed the highest florescence signals in tumor tissues treated with Cy5-RDF-LA/miR NPs relative to Cy5-RDF/miR NPs and naked Cy5-miR- 199a-3p NPs (Fig. 5D ). These results indicate that RDF NPs derivatized with LA led to specific targeting of NPs to HCC.
THERAPEUTIC EFFICACY OF RDF-LA/miR NPs IN HCC XENOGRAFT MOUSE MODEL
Five groups of tumor bearing mice were treated with PBS, naked miR-199a-3p, RDF-LA/NC NPs, RDF/ miR NPs and RDF-LA/miR NPs intravenously (Fig.   6A ). Naked miRNA, RDF-LA/NC NPs and PBS control groups had similar effect and did not show significant regression in tumor volume. RDF-LA/miR Nps treated mice exhibited 55% regression in volume compared to PBS while only 33% regression was observed in RDF/miR Nps treated group (Fig. 6B) . After 30 days, tumors were excised, weighed and imaged (Fig. 6C) . Antitumor efficacy of miR-199a-3p to target protein expression was accessed through western blotting. RDF-LA/miR NPs treated group showed marked reduction in protein expression of mTOR and BCL2 (anti-apoptotic protein), respectively compared to RDF-LA/NC NPs and PBS treated group (Fig. 6D) .
Further, the extent of cell proliferation in tumor tissues was evaluated by quantifying the expression level of Ki-67. Percentage of Ki-67 positive cells were remarkably reduced in RDF-LA/miR NPs compared with other groups. These data were consistent with the HE results of tumor tissues from different groups. Histological analysis showed the presence of proliferative cells, with high nuclear-cytoplasmic ratio, in control tumor group while increased cellular death was observed in case of RDF/miR NPs and RDF-LA/miR NPs. The inhibitory effects of miR-199a-3p in in vivo tumor invasion, metastasis and angiogenesis of HCC were evaluated by expression of its target proteins such as c-Met, MMP2 (Matrix Metalloproteinase 2) VEGFA (Vascular Endothelial Growth Factor A). (26, 27) The expression of c-Met, VEGFA and MMP2 in the tumor tissues of mice treated with RDF-LA/miR NPs were significantly lower than that of the PBS control. Further, reduced CD31 expression (marker for angiogenesis) in tumor tissues of RDF-LA/miR NPs treated mice was observed. These results suggest that RDF-LA/miR NPs effectively suppress tumor growth by inhibiting proliferation, invasion, angiogenesis and inducing cellular death in tumor cells (Fig. 6E) .
We also determined the percentage survival of mice after treatment with different formulations. After 30 days, 75% of mice were survived in RDF-LA/miR NPs treated group while only 50% and 16% in case of RDF/miR NPs and naked miR-199a-3p treated group respectively. These results indicates superior therapeutic efficacy of RDF-LA/miR NPs than RDF/miR NPs and naked miR-199a-3p (Fig. 6F) .
We also investigated the in vivo toxicity of RDF/ miR NPs and RDF-LA/miR NPs in mice after their intravenous administration. No change in bodyweight was observed in mice injected with RDF/miR NPs and RDF-LA/miR NPs compared to control group (Fig.  7A) . Further, histopathological examination using hematoxylin and eosin (HE) staining for major organs (liver, kidney, spleen, heart, lungs) showed no tissue damage or abnormalities (Fig. 7B) . Also, blood biochemistry parameters such as ALT, AST and creatinine were within the normal range for all groups (Fig.  7C) . No significant immune response was elicited in RDF-LA/miR NPs and RDF-LA NPs, as levels of serum inflammatory cytokines such as TNF-a, IL-1b and IL-6 was similar to PBS control group. GM-CSF cytokine concentration was below the detection limit (Supporting Fig. S6 ). These results indicate high biocompatibility of RDF-LA/miR NPs for in vivo applications.
Discussion
Growing evidence has demonstrated the critical role of miRNAs in liver tumorigenesis and other biological processes. miRNAs have emerged as important regulatory molecules for HCC therapy by acting as either tumor suppressors or oncogenes. (4) (5) (6) Several attempts have been made for therapeutic delivery of miRNA using viral and non-viral vectors in HCC. (6, (28) (29) (30) In this study, we describe lactosylated argininedehydrophenylalanine NPs for the selective delivery of miR-199a-3p to liver tumor cells. We found that these RDF-LA/miR NPs not only were able to efficiently deliver miR-199a-3p but also showed antitumor activity both, in vitro and in vivo.
Four peptides based on arginine and histidine and containing DPhe were synthesized, characterized and tested for their ability to form NPs. Out of the four peptides tested, RDF turned out to be most suitable for further investigations.
Site specific delivery of biologically active molecules is prerequisite for achieving a significant therapeutic outcome without harmful side effects to other organs. (31) Ligands for HCC targeting such as aptamers have rapid blood clearance while monoclonal antibodies (mAbs) are costly, have large size, may have batch to batch variability and somewhat restricted by difficulties in their conjugation. (32) On the other hand, carbohydrate based small molecules like galactose, galactosamine, lactobionic acid have been reported to possess high affinity for ASGPR and can easily be conjugated. Therefore, we chose LA which binds to ASGPR leading to internalization of the NPs through receptor mediated endocytosis as the ligand of choice for tumor targeting. (33) Also, LA contains a free carboxylic group which could be exploited for conjugation with the amino terminus of short peptides. Conjugation of LA with RDF NPs was carried out easily by EDC-NHS chemistry, did not alter the morphology of NPs but as expected led to an increase in the size from 20nm to 40nm. However, this increase in size was well within range for reaching the tumor interstitium and exploiting enhanced permeability and retention (EPR). (31) Results of gel retardation assay showed complete binding of miR-199a-3p with RDF-LA NPs at 50:1 ratio (NPs: miRNA w/w). Complexation with miR-199a-3p led to a significant decrease in zeta potential of RDF-LA NPs (from 13.24 6 0.14mV to 2.54 6 0.01 mV) which is a reasonable outcome of the complex formation between negatively charged miRNA molecules and positively charged RDF-LA NPs. It is well know that neutral charge particles are more suitable targets for target receptor binding, NPs internalization and likely to have minimum interactions with serum protein. (34, 35) Next, we evaluated the miRNA loading capacity of RDF-LA NPs and its release from the NPs under in vitro conditions. The loading capacity of NPs (2.9%) was reasonably high and compared well with earlier reported delivery systems. (36, 37) An enhanced release of miRNA at pH 5 as compared to pH 7.4 or in serum was observed. This could be due to reduced charge -charge interactions between RDF-LA NPs and miRNA at pH 5; at this pH the negative charge of miRNA molecules is likely to be significantly reduced. Loading capacity of, and the release of miRNA from its complex with RDF-LA NPs indicated their suitability as possible delivery agent for miRNA. The ability of any NPs based delivery systems to protect their cargos including oligonucleotides in in vivo enzymatic conditions is an important prerequisite parameter for their potential use in clinical applications. (38) Results of stability experiment showed that miR-199a-3p was stable in serum as well as to the action of RNase A.
One of the major obstacles to successful clinical translation of miRNA therapeutics is their efficient delivery in cell cytoplasm through endosomal escape. (30) Cellular uptake experiments using flow cytometry showed an enhanced uptake of RDF-LA/ miR NPs compared to RDF/miR NPs, while a reduced uptake of RDF-LA/miR NPs was observed in lactose pre-treated cells. These results suggested receptor mediated entry of RDF-LA/miR NPs. Further, intracellular localization of Cy3-RDF-LA/miR NPs was investigated using confocal microscopy. We found significantly higher accumulation of Cy3-RDF-LA/ miR NPs in the cytoplasm, indicating their efficient delivery and endosomal escape ability. The enhanced cellular uptake for the targeted NPs than the nontargeted NPs in HCC cells was in agreement with earlier studies which have described the use of LA as the targeting ligand. (19, 39, 40) miRNAs have been shown to have profound effect on a wide variety of cellular processes including cell proliferation, migration and apoptosis. (6) Functional efficacy of RDF-LA/miR NPs in Huh7 cells with regard to these biological activities was investigated. An increased expression of miR-199a-3p and concomitant downregulation of the miR-199a-3p target gene (mTOR) expression in these cells after treatment with RDF-LA/miR NPs was observed. Results of MTT assay showed significantly suppressed cell proliferation on treatment with RDF-LA/miR NPs compared to untreated cells. Likewise, results of wound healing assay demonstrated reduced migration of Huh7 cells upon treatment with RDF-LA/miR NPs. The NPs also showed marked apoptosis with 32% annexin V positive cells. These results were consistent with those published earlier regarding functional activities of miR-199a-3p. (8, 9) However, it may be relevant to point out that Henry et al. showed that cell proliferation inhibition occurred in only CD44 positive HCC cells following transfection with miR-199a-3p. Their findings seem to be supported by the observation that CD44V6 is an essential splice variant of c-Met signaling activation pathway which in turn effects cell proliferation. (41) But, later studies have shown suppressed cell proliferation in miR-199a-3p transfected CD44 negative HCC cells as well. (8, 24, 28, 42) However, these apparently contradictory results could be due to the presence of ICAM-1 expression in HCC cell lines such as HepG2 and Huh7 cells, which can fulfill the function of CD44v6 for activation of c-Met signaling pathway. (43) The major goal of a successful delivery system is to deliver functional cargos in vivo after surpassing all enroute barriers. Results of in vivo biodistribution of RDF-LA/miR NPs demonstrated significantly higher accumulation of NPs in tumor compared to other organs. These results were further supported by significantly higher antitumor efficacy observed with RDF-LA/miR NPs in terms of tumor volume, tumor weight and the survival rate of tumor bearing mice. It is well known that miR-199a-3p downregulates mTOR expression in HCC cells. (9) Results of western blot experiments showed that tumor of RDF-LA/miR NPs treated group had significant downregulation of mTOR expression as compared to relevant control groups of mice. Apart from mTOR, miR-199a-3p is also known to target VEGFA, MMP2 (26) and c-Met (9) which are majorly involved in invasion, metastasis and angiogenesis of HCC cells, (27, 44, 45) Our results of immunohistochemistry showed reduced expression of these proteins in tumors of mice treated with RDF-LA/miR NPs in comparison to those in the control groups, indicating RDF-LA/miR NPs restricted invasion, metastasis and angiogenesis of HCC cells in vivo. Taken together these results clearly suggested that RDF-LA/miR NPs have noticeable therapeutic effect in HCC tumor bearing mice.
Babae et al. have described systemic delivery of miRNA 7 by integrin targeted polyamide NPs with 42% tumor growth inhibition. (46) Also, Chen et al. used single chain antibody fragment (scFv) modified liposome-polycation-hyaluronic acid NPs for systemic delivery of siRNA and miRNA and showed upto 20% reduction in tumor growth. (47) In a recent study, LA conjugated PLGA polymer based NPs used for miRNA 99a delivery, demonstrated HCC tumor regression of 50% in mice xenograft model. (48) In this regard, the observed tumor regression shown by LA derivatized highly biocompatible dipeptide NPs represents a strategy for efficient delivering of miRNA along with significant antitumor efficacy.
Toxicity of drug and/or gene delivery agents is one of the major concerns for their clinical development and several highly efficient delivery agents reported in literature have, more often than not, failed to reach clinical trials. (49, 50) Toxicity of RDF-LA NPs was evaluated by histopathology, biochemical parameters and immune response studies. There were no observable changes in HE staining and levels of AST, ALT and creatinine in RDF-LA treated mice comparison to the relevant the controls. Also, there were no observable differences in the levels of inflammatory cytokines (IL-1b, IL-6 and TNF-a) in mice treated with RDF-LA NPs compared to the control group indicating high biocompatibility and non-immunotoxicity of the NPs.
These results clearly demonstrated that functionalized RDF-LA NPs based on an ultrashort, modified dipeptide may have significantly better properties including ease of synthesis and functionalization, high stability, significant target specificity and high biocompatibility which make them an attractive candidate for their use as delivery system in HCC therapy. Our study paves the way for future investigations using a large cohort of mice and testing a range of doses of RDF-LA/miR NPs for therapeutic potency. It may also be possible to deliver both miRNA and an anticancer drug simultaneously to the tumor site using this peptide based NPs. (38) 
